Results 221 to 227 of about 681,456 (227)

EE339 The Biosimilars’ Economic Evaluation in Contrast With Judicializations’ Economic Impacts of the Pharmaceutical Assistance in Brazil

Value in Health
E Tanaka, GK Tanaka, L. Assunção-Costa, E Blay   +3 more
openaire   +1 more source

The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products,

Reactions Weekly, 2012
openaire   +2 more sources

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

Section 4: Clinical pharmacy services
MJ Carvalho, AR Lopes Calvo, J Oliveira, MR Vaz, MR Ferreira, P Soares   +5 more
openaire   +1 more source

Launching Biosimilar Rituximab: An Industry Opinion on Biosimilar Uptake in Europe

Immunotherapy, 2017
exaly  

TRENDS IN PRICES AND CONSUMPTION OF BRANDED AND GENERIC OR BIOSIMILAR ANTINEOPLASTIC MEDICINES USED FOR SOLID TUMORS TREATMENT IN THE RUSSIAN PHARMACEUTICAL MARKET

2019
A. V. Nikitina, Filipp Vasilievich Gorkavenko, Saybel, Yegor Sergeevich, M. Avxentyeva, M. V. Sura   +4 more
openaire   +1 more source

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD.

American health & drug benefits
openaire   +1 more source

An assessment of the inter-relationships between European patent litigation, regulation and the arrival of biosimilar pharmaceuticals on the European market

2016
openaire   +1 more source